Free Trial

Adaptive Biotechnologies (ADPT) Earnings Date, Estimates & Call Transcripts

Adaptive Biotechnologies logo
$8.33 -0.04 (-0.48%)
Closing price 02/20/2025 04:00 PM Eastern
Extended Trading
$8.39 +0.06 (+0.72%)
As of 02/20/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Adaptive Biotechnologies Latest Earnings Summary

Upcoming Q1
Earnings Date
May. 6After Market ClosesEstimated
Actual EPS
(Feb. 11)
-$0.23 Beat By $0.04
Consensus EPS
(Feb. 11)
-$0.27

Adaptive Biotechnologies released Q4 2024 earnings on February 11, 2025, reporting an EPS of -$0.23, which topped analysts' consensus estimates of -$0.27 by $0.04. With a trailing EPS of -$1.09, Adaptive Biotechnologies' earnings are expected to grow next year, from ($0.94) to ($0.71) per share.

ADPT Upcoming Earnings

Adaptive Biotechnologies' next earnings date is estimated for Tuesday, May 6, 2025, based off prior year's reporting schedules.

Get Adaptive Biotechnologies Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Adaptive Biotechnologies and other key companies, straight to your inbox.

Sign Up
Skip Charts & View Estimated and Actual Earnings Data

ADPT Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

ADPT Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Adaptive Biotechnologies Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20251-$0.27-$0.27-$0.27
Q2 20251-$0.24-$0.24-$0.24
Q3 20251-$0.22-$0.22-$0.22
Q4 20251-$0.20-$0.20-$0.20
FY 20254($0.93)($0.93)($0.93)

Adaptive Biotechnologies Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails
5/6/2025
(Estimated)
-------
2/11/2025Q4 2024-$0.27-$0.23+$0.04-$0.23$46.05M-
8/1/2024Q2 2024-$0.33-$0.31+$0.02-$0.21$38.63M$43.19M
5/7/2024Q1 2024-$0.35-$0.33+$0.02-$0.33$38.78M$41.87M
2/14/2024Q4 2023-$0.32-$0.30+$0.02-$0.12$50.15M$45.78M
11/9/2023Q3 2023-$0.32-$0.35 -$0.03-$0.35$43.26M$37.92M
8/2/2023Q2 2023-$0.33-$0.33--$0.33$44.87M$48.93M
5/3/2023Q1 2023-$0.34-$0.40 -$0.06-$0.40$36.81M$37.65M

Adaptive Biotechnologies Earnings - Frequently Asked Questions

Adaptive Biotechnologies has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, May 5th, 2025 based off last year's report dates. Learn more on ADPT's earnings history.

In the previous quarter, Adaptive Biotechnologies (NASDAQ:ADPT) reported ($0.23) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.27) by $0.04. Learn more on analysts' earnings estimate vs. ADPT's actual earnings.

The conference call for Adaptive Biotechnologies's latest earnings report can be listened to online.
Listen to Conference Call

The conference call transcript for Adaptive Biotechnologies's latest earnings report can be read online.
Read Transcript

Adaptive Biotechnologies (NASDAQ:ADPT) has a recorded annual revenue of $178.96 million.

Adaptive Biotechnologies (NASDAQ:ADPT) has a recorded net income of -$159.49 million. ADPT has generated -$1.09 earnings per share over the last four quarters.

Adaptive Biotechnologies's earnings are expected to grow from ($0.94) per share to ($0.71) per share in the next year.

More Earnings Resources from MarketBeat



This page (NASDAQ:ADPT) was last updated on 2/21/2025 by MarketBeat.com Staff
From Our Partners